Navigation Links
Omeros to Webcast Presentation at Deutsche Bank 35th Annual Health Care Conference
Date:4/29/2010

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Omeros Corporation (Nasdaq: OMER), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros, will present at the Deutsche Bank 35th Annual Health Care Conference in Boston on May 4, 2010 at 2:50 p.m. EDT.  The presentation will be webcast.  The live or archived webcast can be accessed on the "Events" page of the Company's website at www.omeros.com.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform and one from its Addiction program, the most advanced of which is in Phase 3 clinical trials. Omeros may also have the near-term capability, through its GPCR program, to add an unprecedented number of wholly new drug targets to the market
'/>"/>

SOURCE Omeros Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
2. Omeros Appoints David A. Mann to its Board of Directors
3. Affitech and Omeros Enter Into Antibody Discovery and Development Agreement
4. Omeros and BlueCrest Announce $20 Million Debt Facility
5. Omeros Announces Results from a Phase 1 Study of OMS201 for Use During Urological Surgery
6. Omeros Awarded Grant from The Michael J. Fox Foundation to Evaluate Novel Parkinsons Disease Target
7. Omeros Appoints New Vice President of Clinical Development
8. Omeros Announces Positive Clinical Results of Phase 1/Phase 2 Trial of OMS302 for Use During Ophthalmologic Surgery
9. Omeros Commences Initial Public Offering of Common Stock
10. Omeros Corporation Reports Third Quarter 2009 Financial Results and Development Highlights
11. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... , Aug. 3, 2015  ArroGen Group, ... its new Fingerprint Molecular Identification™ (FMID) technology Aug. ... conference in Sacramento, Calif. ... science, will enable law enforcement agents, district attorneys ... of criminal suspects. By analyzing chemical ...
(Date:8/3/2015)... WESTWOOD, Mass. , Aug. 3, 2015  Merck ... company for innovative and top-quality high-tech products in the ... together with the US-based company Nano-C, their development and ... field of organic photovoltaics (OPV). Merck KGaA, Darmstadt, ... participate in the growing OPV sector. Novel ...
(Date:8/3/2015)... 2015   Intrexon Corporation (NYSE: XON ... second quarter 2015 financial results after the market closes ... will host a conference call at 5:30 PM ET ... update. The conference call may be accessed ... asking to join the "Intrexon Corporation Call."  Participants may ...
(Date:7/31/2015)... , July 31, 2015 In today,s ... that help them drive positive health outcomes, improve ... source of patient care in their communities. At ... tradeshow and conference, AmerisourceBergen announced a new set ... Services Administration Organization and help independent pharmacies endure ...
Breaking Biology Technology:ArroGen Previews New Fingerprint Molecular Identification Technology 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 2Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 3Merck KGaA, Darmstadt, Germany, and Nano-C Present Enhanced Materials for Organic Photovoltaics 4Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 2AmerisourceBergen Unveils Suite of Enhanced Capabilities for Independent Pharmacies at ThoughtSpot 2015 3
... VALENCIA, Calif., June 16 MannKind,Corporation (Nasdaq: MNKD ), ... announced today that it,will present at upcoming conferences., ... 23, 2008 at 11:45 AM (Eastern ... Island, Massachusetts, -- 2nd Annual Jefferies Healthcare Conference ...
... FRANCISCO, June 16 The Endocrine Society, an,international association ... for security analysts. The call,originated from ENDO 08, the ... in San Francisco. The Society has over 14,000 members ... report on the latest,advances in endocrine research and clinical ...
... 16 Celator Pharmaceuticals today,announced that John Bennett, ... the BIO Business Forum during the Biotechnology Industry,Organization ... will,provide a corporate overview and an update on ... on Wednesday, June 18,2008 at 3:30 PDT in ...
Cached Biology Technology:'Breakthroughs Ahead,' Endocrine Society Tells Security Analysts 2
(Date:7/9/2015)... 07, 2015 Research ... of the "Biometrics for Banking; Market & ... report to their offering. The adoption ... this growth and the forecast is that by ... for companies involved in delivering biometric systems to ...
(Date:7/8/2015)... , July 8, 2015  Trovagene, Inc. (NASDAQ: ... diagnostics, today announced the launch of a study ... Precision Cancer Monitoring℠ (PCM) technology for predicting response ... or a combination of the novel immunotherapy agents ... a PD-1 inhibitor. The 50-patient study will be ...
(Date:7/2/2015)... June 25, 2015 ... addition of the "Natural Language Processing Market ... IVR, OCR, Pattern & Image Recognition) - Worldwide ... The key vendors occupying the market ... Corporation, Microsoft Corporation, NetBase Solutions, SAS Institute Inc., ...
Breaking Biology News(10 mins):Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Natural Language Processing Market by Type (Rule-Based, Statistical, and Hybrid), Technologies (Recognition, IVR, OCR, Pattern & Image Recognition) - Worldwide Forecast to 2020 2
... asthma has been shown to help reduce the formation ... is implicated in the development of Alzheimer,s disease, according ... The researchers published their findings, "Pharmacologic Blockade of 5-Lipoxygenase,Improves ... in the American Journal of Pathology . ...
... The long tendrils of this woody vine, or liana, ... But kudzu may be no match for the lianas of ... studies show that lianas are overgrowing trees in every instance. ... forest ecosystems. Tropical forests contain more than half of ...
... The Pancreatic Cancer Action Network and the American Association ... and E. Scott Seeley, M.D., Ph.D., the 2011 Pancreatic ... each totaling $600,000 over five years, will be formally ... April 2-6. "Because of the poor prognoses and ...
Cached Biology News:Asthma drug could help control or treat Alzheimer's disease 2Stranglers of the tropics -- and beyond 2Stranglers of the tropics -- and beyond 3Pancreatic Cancer Action Network-AACR Pathway to Leadership Grants awarded to early-career investigators 2Pancreatic Cancer Action Network-AACR Pathway to Leadership Grants awarded to early-career investigators 3Pancreatic Cancer Action Network-AACR Pathway to Leadership Grants awarded to early-career investigators 4
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
QPRT Antibody...
This antibody is specific for human J-chain as defined by ELISA assay using purified human immunoglobulin fragments as solid phase target antigen....
Biology Products: